BIOAGE LABS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
BIOAGE LABS, INC. (BIOA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$551.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- BIOAGE LABS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$551.00K.
- BIOAGE LABS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$205.00K, a 1178.95% decline year-over-year.
- BIOAGE LABS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $3.00K, a 88.46% decline year-over-year.
- BIOAGE LABS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $63.00K, a 8.62% increase year-over-year.
- BIOAGE LABS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $33.00K, a 59.26% decline from fiscal 2024.
- BIOAGE LABS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $81.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$551.00K 10-Q · filed 2026-08-05 | -$756.00K 10-Q · filed 2026-08-05 | -$753.00K derived: sum of 3 quarters · filed 2026-08-05 | -$690.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$205.00K 10-Q · filed 2026-05-08 | -$202.00K derived: sum of 2 quarters · filed 2026-05-08 | -$139.00K derived: sum of 3 quarters · filed 2026-05-08 | -$191.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $66.00K derived: sum of 2 quarters · filed 2026-03-24 | $14.00K derived: sum of 3 quarters · filed 2026-08-05 | $33.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $63.00K 10-Q · filed 2025-11-06 | $11.00K derived: sum of 2 quarters · filed 2026-08-05 | $30.00K 10-Q · filed 2025-11-06 | $56.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$52.00K 10-Q · filed 2026-08-05 | -$33.00K 10-Q · filed 2026-08-05 | -$7.00K derived: sum of 3 quarters · filed 2026-08-05 | $51.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $19.00K 10-Q · filed 2026-05-08 | $45.00K derived: sum of 2 quarters · filed 2026-05-08 | $103.00K derived: sum of 3 quarters · filed 2026-05-08 | $85.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $84.00K derived: sum of 2 quarters · filed 2026-03-24 | $66.00K derived: sum of 3 quarters · filed 2026-03-24 | $81.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $58.00K 10-Q · filed 2025-11-06 | $40.00K derived: sum of 2 quarters · filed 2025-11-06 | $55.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$18.00K 10-Q · filed 2025-08-06 | $3.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $21.00K 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |